Phase II Trial of Treatment for Depressive Disorder in the Works

February 2011
Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p57
Trade Publication
The article reports that AstraZeneca PLC and Targacept Inc. have enrolled the first patient of a phase II clinical trial of TC-5214, a nicotinic channel blocker as treatment for patients with major depressive disorder (MDD) who do not respond to antidepressant therapy in London, England.


Related Articles

  • AZT Drug Candidate Enters Home Stretch.  // Bioworld Week;6/28/2010, Vol. 18 Issue 26, p4 

    The article reports on the use of depression drug candidate TC-5214 from Targacept Inc. and AstraZeneca PLC in the U.S.

  • Targacept to retain full rights for schizophrenia drug.  // PharmaWatch: CNS;Jun2011, Vol. 10 Issue 6, p22 

    The article reports on the full rights retained by Targacept Inc. on TC-5619 schizophrenia drug after AstraZeneca PLC decided not exercise its option to license TC-5619.

  • Targacept Inc (Winston-Salem NC) said it received a $200 million payment from partner AstraZeneca Plc for work on a developing treatment for major depressive disorder.  // MondayMorning;1/18/2010, Vol. 18 Issue 2, p22 

    The article reports on the 200 million dollar-payment received by biopharmaceutical company Targacept Inc. from its partnership with pharmaceutical company AstraZeneca PLC for the development of depressive disorder drug candidate TC-5214.

  • Targacept Down on Disappointing Phase IIb.  // Bioworld Week;12/15/2008, Vol. 16 Issue 50, p3 

    The article reports on the disappointment of Targacept Inc. for the failure of its alpha4beta2 neuronal nicotinic receptor (NNR) compound AZD3480 to improve cognitive dysfunction in schizophrenia patients in the U.S. It notes that partner AstraZeneca has planned to make a skeptical decision on...

  • AstraZeneca/Targacept: another nail in the coffin for TC-5214.  // PharmaWatch: CNS;Feb2012, Vol. 11 Issue 2, p11 

    The author discusses the result of the Phase III trials for innovative nicotinic receptor antagonist TC-5214 of AstraZeneca PLC and Targacept Inc. The author mentions that the drug has failed to demonstrate efficacy as an add-on to antidepressants in patients with major depressive disorder. The...

  • AstraZeneca's Mood Lifting; Targacept Gets Sunny, Too. Osborne, Randy // BioWorld Insight;7/12/2010, Vol. 18 Issue 28, p1 

    The article reports that AstraZeneca PLC's adjunctive compound TC-5214 for major depressive disorder is beginning its Phase III clinical trials. It notes that the development is giving hope to the investors of AstraZeneca's partner Targacept Inc. in view of the patent expiration for Seroquel IR...

  • Targacept, AZT Depression Drug Candidate Enters Home Stretch. Hollingsworth, Catherine // BioWorld Today;6/24/2010, Vol. 21 Issue 121, p1 

    The article reports on the enrollment of the first patient in the Phase III trial for TC-5214, the depression drug candidate from Targacept Inc. and AstraZeneca. Phase II trial of the drug showed positive results in the use of the drug as an add-on therapy for patients who did not respond well...

  • Down but not out for TC-5214 in depression.  // PharmaWatch: CNS;Dec2011, Vol. 10 Issue 12, p13 

    The article focuses on the failure of the antidepressant TC-5212 from AstraZeneca PLC and Targacept Inc. in the first Phase III clinical trial. It mentions that the antidepressant has failed its demonstration on the Montgomery-Asberg Depression Rating Scale (MADRS) on 780 patients. Furthermore,...

  • Targacept to Report 3rd Qtr 2011 Financial Results on Nov 1 2011.  // Biomedical Market Newsletter;10/31/2011, Vol. 21, p1232 

    The article reports that biopharmaceutical firm Targacept Inc. has scheduled to report its financial results for the third quarter 2011 via a conference call after the markets close on November 1, 2011. It will provide an update on the company's product development programs, business activities,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics